地诺单抗用于绝经后低骨密度女性。 - Suppr | 超能文献

Denosumab in postmenopausal women with low bone mineral density.

作者信息

Rifkin William D

出版信息

N Engl J Med. 2006 Jun 1;354(22):2390-1; author reply 2390-1.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Denosumab in postmenopausal women with low bone mineral density.地诺单抗用于绝经后低骨密度女性。

N Engl J Med. 2006 Jun 1;354(22):2390-1; author reply 2390-1.

2

Denosumab in postmenopausal women with low bone mineral density.地诺单抗用于绝经后低骨密度女性。

N Engl J Med. 2006 Feb 23;354(8):821-31. doi: 10.1056/NEJMoa044459.

3

Denosumab update.地诺单抗最新情况

Curr Opin Rheumatol. 2009 Jul;21(4):369-73. doi: 10.1097/BOR.0b013e32832ca41c.

4

Denosumab for postmenopausal osteoporosis?地诺单抗用于绝经后骨质疏松症？

Drug Ther Bull. 2012 Jan;50(1):6-8. doi: 10.1136/dtb.2011.02.0080.

5

Denosumab in postmenopausal women with low bone mineral density.地诺单抗用于绝经后低骨密度女性。

N Engl J Med. 2006 Jun 1;354(22):2390-1; author reply 2390-1. doi: 10.1056/NEJMc060819.

6

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.地舒单抗对绝经后妇女骨密度和骨转换的影响。

Pharmacotherapy. 2011 May;31(5):510-23. doi: 10.1592/phco.31.5.510.

7

Denosumab, osteoporosis, and prevention of fractures.地诺单抗、骨质疏松症与骨折预防

N Engl J Med. 2009 Nov 26;361(22):2189; author reply 2190-1.

8

Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.地舒单抗治疗绝经后低骨密度和骨质疏松症妇女的临床疗效和安全性：一项荟萃分析。

Semin Arthritis Rheum. 2011 Oct;41(2):178-86. doi: 10.1016/j.semarthrit.2011.03.005. Epub 2011 May 26.

9

[Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].[地诺单抗。首个用于治疗骨质疏松症的核因子κB受体活化因子配体抑制剂]

Med Monatsschr Pharm. 2010 Oct;33(10):370-5.

10

Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.比较唑来膦酸与阿仑膦酸钠治疗绝经后骨质疏松症的临床疗效和安全性：一项荟萃分析。

Int J Clin Pract. 2012 Apr;66(4):399-408. doi: 10.1111/j.1742-1241.2011.02806.x. Epub 2012 Feb 7.

引用本文的文献

1

C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway.C-Src通过激活ERK和Akt通路介导RANKL诱导的乳腺癌细胞迁移。

Oncol Lett. 2012 Feb;3(2):395-400. doi: 10.3892/ol.2011.487. Epub 2011 Nov 16.